

























































published: 05 September 2014
doi: 10.3389/fimmu.2014.00427
The intestinal microbiome in early life: health and disease
Marie-Claire Arrieta1, LeahT. Stiemsma2, Nelly Amenyogbe2, Eric M. Brown1 and Brett Finlay 1,3,4*
1 Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada
2 Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada
3 Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada
4 Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada
Edited by:
Arnaud Marchant, Université Libre de
Bruxelles, Belgium
Reviewed by:
Rae Ritchie, Bioscience Vaccines Inc.,
USA
Paola Massari, Boston University,
USA
Tobias Strunk, University of Western
Australia, Australia
*Correspondence:
Brett Finlay , Michael Smith
Laboratories, University of British
Columbia, #301 – 2185 East Mall,
Vancouver, BC V6T 1Z4, Canada
e-mail: bfinlay@mail.ubc.ca
Human microbial colonization begins at birth and continues to develop and modulate in
species abundance for about 3 years, until the microbiota becomes adult-like. During the
same time period, children experience significant developmental changes that influence
their health status as well as their immune system. An ever-expanding number of articles
associate several diseases with early-life imbalances of the gut microbiota, also referred
to as gut microbial dysbiosis. Whether early-life dysbiosis precedes and plays a role in dis-
ease pathogenesis, or simply originates from the disease process itself is a question that
is beginning to be answered in a few diseases, including IBD, obesity, and asthma. This
review describes the gut microbiome structure and function during the formative first years
of life, as well as the environmental factors that determine its composition. It also aims
to discuss the recent advances in understanding the role of the early-life gut microbiota
in the development of immune-mediated, metabolic, and neurological diseases. A greater
understanding of how the early-life gut microbiota impacts our immune development could
potentially lead to novel microbial-derived therapies that target disease prevention at an
early age.
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INTRODUCTION
The infant gut undergoes important developmental stages that
are entirely dependent upon the colonization with microorgan-
isms, beginning at birth. Experiments in germ-free animal models
have shown that microbial colonization induces anatomical devel-
opment of the intestinal epithelium into the typical microvilli
pattern, increases epithelial cell turnover rates, and kick-starts
the maturation of the gut-associated lymphoid (immune) tissue
(GALT) (1, 2). Functionally, germ-free mice do not develop oral
tolerance (3) and mice treated with antibiotics are far more sus-
ceptible to intestinal pathogens (4–6). Furthermore, upon antibi-
otic treatment, several animal models show either an exacerbated
or improved phenotype of immune-mediated diseases, includ-
ing asthma (7) and type 1 diabetes (8), emphasizing the role of
microbiota in the development of immune-mediated diseases.
The behavior of children in the first 3 years of life clearly pro-
motes significant exposure to microbes: feeding directly from
maternal skin, constant introduction of hands, feet, and other
objects to mouth, and contact of hands onto floor surfaces, espe-
cially during crawling and early walking stages. Children also suffer
more infectious diseases than adults. Not surprisingly, the micro-
biota in children under 3 years of age fluctuates substantially and
is more impressionable to environmental factors than the adult
microbiota (9). Modern changes in lifestyle, including improved
sanitization, cesarean sections, antibiotic usage, and immuniza-
tions are among some of the factors that can shift the microbiota,
and are being studied as potential drivers of the sudden increase
in immune-mediated diseases in the developed world. It has been
hypothesized that there is a “critical window” early in life during
which the microbiota can be disrupted in a way that may favor
the development of disease later in life (10). This has been shown
to be the case in an animal model of asthma, in which antibiotic
treatment exclusively during the perinatal period leads to a more
severe disease phenotype (7).
The aim of this review is to summarize the latest findings of
childhood microbiota studies focusing on the first 3 years of life.
In addition, we compile some of the most relevant prenatal, peri-
natal, and postnatal events that are known to alter the early-life gut
microbiome. We also discuss the increasing evidence indicating a
role for microbiota changes during early-life impacting the devel-
opment of intestinal and extra intestinal diseases. As the study
of the microbiota has changed drastically with the emergence of
culture-independent techniques, we begin this review by describ-
ing the high-throughput sequencing methods currently used to
analyze microbial communities.
METHODS TO STUDY THE MICROBIOTA
Our concept of the microbiota has profoundly expanded with the
emergence of molecular methods to study microbial communi-
ties. These methods have eclipsed the small proportion of bacterial
groups capable of growing in cultures. Although in other natural
environments, the cultivation rates are slightly higher (11, 12),
cultivability of human-associated communities remains very low
(13, 14). These methods have also led to the discovery of novel
taxa, such as the phylum TM7 in the human intestinal tract and
other body sites (15–18). It is beyond the scope of this review to
discuss all methods to study the microbiota as there are already
reviews dedicated to this topic (19–21). Instead, we discuss the
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most relevant methods used in microbiota research, including tar-
geted approaches like 16S rRNA gene next-generation sequencing
(NGS), as well as the large-scale metagenomics approach, also
known as shot-gun sequencing.
16S rRNA GENE NGS – MICROBIOTA COMMUNITY SURVEYS
The current gold standard for microbial community analysis is
the amplification of the 16S rRNA gene, although other bacteria-
specific targets such as the ribosomal 23s subunit and the internally
transcribed spacer (ITS) 16S-23S spacer region (22, 23) have been
used. The 16s rRNA gene has the advantages of encoding several
conserved regions that are exclusive to all bacteria and hypervari-
able regions that confer specificity to a large number of bacterial
species. Current taxonomy reference databases such as SILVA (24)
contain over 3 million aligned 16S sequences. The typical 16S
community analysis involves DNA or RNA extraction, amplifica-
tion, standardization, library construction, sequencing, and sub-
sequent bioinformatic analysis. The choice of primers to amplify
the desired region of the 16S gene, as well as the extraction proto-
col used, may introduce bias to the microbial composition results.
For example, primers that target regions V1–V2 fail to amplify
important bacterial groups, such as Bifidobacterium. The use of
these primers led to the erroneous conclusion that Bifidobacteria
were an unimportant bacterial group in the infant intestine (25).
Although there is still no consensus on this, comparative analysis
with full length Sanger sequencing of the 16S rRNA gene supports
the use of primers that amplify the V4 region (26), as they yield
the most taxonomically informative sequences (27).
Currently, there are two main sequencing platforms being
used by most research groups: the Roche 454 pyrosequencer (GS,
FLX, and FLX Titanium) and the Illumina sequencer (MiSeq and
HiSeq2000; Illumina Inc., San Diego, CA, USA). In brief, 454
pyrosequencing allows reading DNA fragments of up to 500 bp,
allowing the coverage of multiple hypervariable V regions, there-
fore improving the taxonomic resolution of the dataset. The Illu-
mina platform provides sequencing of DNA fragments of up to
150 bp in length but it sequences 10–100 more samples, at a much
higher sequencing depth and lower cost than the 454 pyrose-
quencer. By choosing the appropriate primers, one can achieve
an overlap in the sequences, reducing the sequencing error, and
increasing the taxonomic information that can be obtained from
the reads. Principal component analysis from a large cohort study
that used both 454 and Illumina platforms showed that reads
from Illumina clustered very close to the reads obtained from full
length Sanger sequencing, whereas reads from 454 pyrosequencing
clustered separately (28).
There is not a sequencing technique that is considered gold
standard yet, but it is very important to choose the sample prepa-
ration protocols and sequencing platforms that will most benefit
each study, taking into consideration the environment sampled,
the number of samples, cost, and depth of sequencing desired,
among other factors.
METAGENOMICS
While 16S rRNA gene analysis of the microbial communities
gives a survey of the bacteria present in a particular environ-
ment, it fails to provide any functional information. For human
clinical studies, this means that one cannot infer a possible mech-
anism that explains the associations between differences in micro-
bial communities and particular disease states. One approach
to obtain functional biochemical information is metagenomics.
These large-scale studies aim to provide a gene-based inventory
of the microbial community. It involves sequencing of sheared
genomic DNA without any previous amplification, also known as
shot-gun sequencing. To avoid missing the genetic information
from very low abundant species, metagenomic sequencing must
be done to a very high depth. This was evidenced in the recent
Human Microbiome Project study, in which each sample yielded
~107 reads (29). The same NGS platforms discussed for targeted
amplicon studies are used in metagenomic sequencing. The short
sequences obtained are assembled into longer contiguous reads
(contigs) and compared to databases of known genes, such as the
NIH Genbank. There are also databases, such as the Kyoto Ency-
clopedia of Genes and Genomes (KEGG) (30) that organize the
genes into biochemical pathways.
The superiority of nucleic acid-based methods to study the
microbiota over culture-based methods is very well established.
Although methods like metagenomics remain technically sophis-
ticated and expensive to many laboratories, NGS of the 16S rRNA
gene is an affordable and a very informative choice.
EARLY-LIFE GUT MICROBIAL COMPOSITION
Age is the major driver of differences in gut microbiota in sev-
eral human studies (31). Using sequential fecal sampling from
one infant during the first two and a half years of life, and two
large cohort human microbiome studies across North America,
Africa, South America, and Europe, it is apparent the gut micro-
biome is highly unstable during the first 3 years of life (9, 32, 33).
Children younger than 3 years of age have a significantly lower
diversity index compared to adults, with ~1000 operational taxo-
nomic units (OTUs) detected in the first year of life, compared to
almost 2000 OTUs after this. However, while the gut microbiota
of infants is dominated by fewer bacterial species, the interindi-
vidual variability in this age group is significantly higher than in
adults (33).
The newborn intestine at birth is an aerobic environment where
only facultative anaerobes, such as members of the Enterobacteri-
aceae family can grow. In a matter of days, however, the intestinal
lumen turns anaerobic, allowing for strict anaerobes, such as Bifi-
dobacterium, Clostridium, and Bacteroides to colonize (34). During
the first few weeks, the microbiota of the newborn gut resembles
the maternal skin and vaginal microbiome, with Enterococcaceae,
Streptococcaceae, Lactobacillaceae, Clostridiaceae, and Bifidobac-
teriaceae being predominant bacterial taxa. During the first few
months, the diet of the infant is almost exclusively milk, favor-
ing milk oligosaccharide fermenters, such as Bifidobacterium to
thrive. Many bifidobacterial species have been isolated from the
infant gut (35–37) and it is considered the most prevalent bac-
terial group at this stage (31). Weaning and/or introduction of
solids foods mark another rapid and important shift in gut micro-
biota. The introduction of a variety of nutrients, many of which
are polysaccharides not digested by host enzymes, triggers an
increase in abundance of Bacteroides, Clostridium, Ruminococcus,
and a decrease in Bifidobacterium and Enterobacteriaceae (9, 38).
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FIGURE 1 | Stages of microbial colonization of the infant and child
intestine. Most abundant bacterial families are depicted in circles, where
the size of the circle is proportional to the relative abundance of the
bacterial taxa at each growth stage. The intestinal microbiota of the
newborn is initially colonized by Enterobacteria. In the days after, strict
anaerobic bacteria dominate the microbial community. During the first
month, bifidobacterial species predominate in the gut, but the introduction
of solid foods at around 4–6 months is accompanied by an expansion of
clostridial species (Lachnospiracea, Clostridiaceae, and Ruminococcaceae).
Members of the Ruminococcaceae family continue to increase in
abundance in the following months. By 2–3 years of age, the microbiota
composition consists of mainly Bacteroidaceae, Lachnospiraceae, and
Ruminococcaceae, which then remains stable into adulthood.
In the ensuing 12–30 months, the infant gut microbiota pro-
gresses into an adult-like gut microbiota abundant in Ruminococ-
caceae, Lachnospiraceae, Bacteroidaceae, and Prevotellaceae (31)
(Figure 1).
Many factors determine the establishment and composition of
microbial communities in all mucose, including the gut. The most
important microbial inoculum occurs at birth and shortly after-
ward. However, the type of diet babies and toddlers ingest, their
geographical location, and the use of antibiotics during this period
of life can have life-long effects on the composition and function
of their gastrointestinal microbiota. Birth was once thought to be
the first microbial exposure to the infant, but there is now suffi-
cient evidence to support that prenatal microbial exposure occurs.
The following section begins by exploring in utero encounters with
microorganisms.
FACTORS THAT INFLUENCE THE DEVELOPMENT OF THE GUT
MICROBIOTA IN CHILDREN
PRENATAL EXPOSURE
The development of the microbiota begins well before the infant
is born. Contrary to what was previously thought, amniotic fluid
is not sterile (39, 40). In some cases, bacterial presence in the
amniotic fluid is associated with a diseased state. Mycoplasma and
Ureaplasma in the amniotic fluid are frequent isolates associated
with health detriments such as chorioamnionitis, pre-term deliv-
ery, and necrotizing enterocolitis (NEC) (41–43). Also, women
with vaginal infections are much more likely to deliver pre-term
(PT) babies (44). Aside from this, bacteria are also often detected in
the amniotic fluid and placentas of full-term healthy infants (45–
47). Other phyla detected in amniotic fluid and placenta overlap
with phyla commonly found in the oral microbiota: Firmicutes,
Bacteroidetes, Actinobacteria, Proteobacteria, and Fusobacteria
(40, 48). Meconium is also not sterile (49–51), which supports
the notion that microbes in the amniotic fluid have access to
the unborn fetus. A recent study compared meconium micro-
biota of pre-term infants to separate datasets of amniotic, vaginal,
and oral cavity microbiotas, finding that most overlap between
the meconium was from amniotic datasets (52). The bacter-
ial taxa found in meconium using both culture-dependent and
independent approaches overlap with adult intestinal microbiota.
Enterobacteriaceae (including Escherichia coli and Shigella spp.),
Enterococci, Streptococci, Staphylococci (including Staphylococcus
epidermidis), and Bifidobacteria have been detected in healthy, full-
term infants (50, 53). Furthermore, administration of Enterococcus
faecium to pregnant rats allowed for isolation of the same bacte-
ria from the meconium of term pups immediately after birth by
caesarian section (53). Thus, while exposure to pathogenic vaginal
microbes may be considered infectious events, prenatal exposure
to fecal microbes is likely a natural part of in utero development.
How these microbes gain access to the uterus remains unknown,
although bacterial translocation from the gut into the bloodstream
and then to the uterus is one theory that has been proposed, but
not tested experimentally yet (54).
MODE OF DELIVERY
Approximately 26% of infants born in Canada are born by cesarean
section (55) and this percentage is equal or higher in many other
developed countries. The early colonization patterns of cesarean
section born infants differ greatly from children born vaginally
(34, 56). Knight et al. showed that the first microbiotas of human
infants are structured mainly by their mode of delivery, and differ-
ences in the bacterial populations within the infant gut are similar
to the type of microbiota that the child encounters at birth (31,
56). In fact, post-birth 16S rRNA sequencing data conducted by
Knight et al. demonstrate how similar the infant gut microbiota
is to the mother’s vaginal or skin microbiota, depending on their
mode of birth (56). Additionally, analysis of fecal samples from
children 3 days after birth by temporal temperature and dena-
turing gradient gel electrophoresis (TTGE and DGGE) displayed
significant differences in the bacterial populations within the guts
of cesarean and vaginally delivered infants (57). Cesarean born
infants harbored less Bifidobacterium and Bacteroides species com-
pared to children born vaginally (57–59). Also, the gut microbiota
of cesarean delivered infants at 24 months of age is less diverse than
those delivered vaginally (60). The authors hypothesize that this
drop in diversity may be due to delayed colonization of the gut by
Bacteroidetes, as some C-section delivered infants showed no signs
of Bacteroidetes colonization until 1 year of age (60). These dif-
ferences are not, however, apparent in pre-term infants. Although
a shorter gestation time is associated with a higher prevalence
of Clostridium difficile and Staphylococcus species (59), delivery
mode has little effect on the development of the premature infant
gut microbiota (61). It may also be that the colonization patterns
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differ in infants born prematurely due to an increase in antibi-
otics and various medical treatments administered in the neonatal
intensive care unit (NICU) (62, 63).
With the establishment of varying gut microbiotas among
infants born vaginally or by C-section comes the subsequent devel-
opment of various immunological disorders associated with mode
of birth. Bager et al. show that cesarean birth is associated with a
higher risk of development of inflammatory bowel disease (IBD)
between 0 and 14 years of age regardless of parental history of
IBD (64). Blustein et al. conducted a study including 10,219 chil-
dren (926 born by C-section) and found that cesarean delivery
was consistently associated with adiposity at 6 weeks of age and
this association was even stronger if the children were born from
obese mothers (65). Additionally, by age 11 these children were
1.83 times more likely to be overweight or obese (65). Further-
more, Decker et al. found that children born by cesarean section
also have an enhanced risk for developing celiac disease (66). Gut
microbial dysbiosis has been the most accepted explanation for
the association of delivery mode with disease outcome, but more
research is needed to adequately support these hypotheses, as these
remain as association studies.
BREASTFEEDING AND FORMULA FEEDING
Human milk satisfies the nutritional requirements of the infant
and confers protection against pathogens through the transmis-
sion of maternal antibodies (IgA) and other antimicrobial factors
(67–72). The World Health Organization (WHO) recommends
exclusive breastfeeding of children up to 6 months of age in
order to ensure that the growing infant receives the full nutri-
tional benefits of breast-milk (73). A number of studies have
compared the effects of breast versus formula feeding (74–76).
Human breast-milk harbors its own microbial consortium that
is passed on to the infant along with complex non-digestible
human milk oligosaccharides (HMOs) that promote the prolif-
eration of specific gut microbes (77). An infant who consumes
approximately 800 mL of human breast-milk per day is thought
to ingest between 1× 105 and 1× 107 commensal bacteria (78),
however, the origin of these commensals remains unclear. Bacte-
rial transfer from the mother’s skin during suckling is essentially
unavoidable, but a number of studies also support the entero-
mammary pathway hypothesis, wherein bacteria from the mater-
nal gut may reach the mammary glands via maternal dendritic
cells and macrophages (79). Pyrosequencing of breast-milk from
seven mothers revealed the presence of DNA from a number of
major gut-associated bacteria (e.g., Bacteroides and Clostridia)
(80) and it also identified a number of gut-associated bacterial gen-
era shared between the maternal feces, breast-milk, and neonatal
feces (79). Furthermore, Martin et al. confirmed that breast-milk
and infant feces from mother-infant pairs share the same bacte-
rial strains (81). Regardless of the origin of these gut-associated
commensals, a number of studies have attempted to identify the
mechanisms by which breastfeeding promotes overall immune
health via the entero-mammary pathway (67, 81–84). Compar-
isons between breast-fed and formula-fed infants show that breast-
fed infants tend to contain a more uniform population of gut
microbes (84). For example, Bifidobacteria and Lactobacillus tend
to dominate the guts of breast-fed infants whereas formula-fed
infants exhibit higher proportions of Bacteroides, Clostridium,
Streptococcus, Enterobacteria, and Veillonella spp. (82–85).
Another area of research regarding formula enrichment is in
HMOs and their effects on with the infant gut microbiota. HMOs
are considered a type of prebiotic as they promote the growth
and proliferation of beneficial commensals and consequently, pre-
vent pathogen colonization of the infant gut and exert positive
health effects (86). Certain gut-associated bacterial populations
such as Bifidobacterium spp. possess gene clusters dedicated to
the metabolism of these substrates (87, 88). An in vitro study
assessed HMO consumption by Bifidobacterium spp., E. coli, and
Clostridium perfringens and found that only the Bifidobacterium
spp. were able to effectively metabolize HMOs (89). Furthermore,
the metabolism of these substrates resulted in the production of
lactate and short-chain fatty acids (SCFA), which in turn increased
the acidity of the surrounding environment, an important fac-
tor in preventing pathogen invasion (89). Although Bifidobacteria
tend to dominate the guts of breast-fed infants, HMOs are con-
sumed by other bacterial taxa and consequently play a large role
in the colonization of the infant gut by various microbial species.
Unlike Bifidobacterium spp., Bacteroides spp. (e.g., Bacteroides frag-
ilis and Bacteroides vulgatus) consume a broad range of HMO
glycans (90). A piglet model study investigated the role of for-
mula supplementation with an HMO prebiotic mixture on the
gut microbiota and overall health after rotavirus infection (91).
The group found that piglets fed the supplemented formula versus
those fed formula alone had an increased abundance of butyrate-
producing bacteria in the Lachnospiraceae family in addition to
a reduced duration of rotavirus-induced diarrhea (91). Contin-
ued research regarding the role of infant feeding methods in the
development of the gut microbiota will likely shed light on the
immune and metabolic mechanisms that promote overall infant
health.
INTRODUCTION TO SOLID FOODS
The introduction of solid foods into the infant gastrointestinal
tract (GIT) plays a significant role in the development of the
early-life gut microbiota. The gut microbiota conducts a much
broader range of metabolic processes than the mammalian cells of
the GIT, as it produces a number of degradative enzymes that are
not encoded by mammalian genomes (92). Consequently, non-
digestible carbohydrates such as plant cell wall polysaccharides,
cellulose, and xylans can be broken down and fermented by the
gut microbiota (93). SCFAs (the most common being butyrate,
acetate, and propionate) are end products of microbial fermenta-
tion and are essential energy sources for cells in the mammalian
gut in addition to being precursors for gluconeogenesis, liponeo-
genesis, and protein and cholesterol synthesis (94). The types
and amounts of SCFAs produced as well as the prevalence of
gut microbial species that produce them are determined by the
types of carbohydrates consumed (93–95). Additionally, changes
in diet can shift the types and prevalence of microbial species in
the gut, as certain microbial species may be better equipped to
utilize specific substrates (i.e., inulin and fructo-oligosaccharides
promote Bifidobacterium growth) (93). Conversely, some bacterial
phyla (e.g., Bacteroidetes) produce numerous carbohydrate-active
enzymes that cover a large spectrum of substrates allowing them
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to switch between energy sources depending on what is available
to them (96).
The first introduction of infants to solid foods occurs during
weaning (complimentary feeding) when infants are exposed to
a much larger array of non-digestible carbohydrates than those
present in breast-milk or formula (38). As discussed above, shifts
in diet can significantly alter the gut microbiota due to the pres-
ence of new substrates that promote the survival and prolifera-
tion of varied types of microbial species (38, 93). Additionally,
the pancreatic function, small intestinal absorption, and colonic
fermentation abilities of the weaning infant mature with the intro-
duction of non-digestible carbohydrates – changing the overall
conditions of the digestive tract and the materials that eventually
reach the developing colon (97). Fallani et al. used fluorescent
in situ hybridization (FISH) to characterize the gut microbiotas
of 531 infants across Europe before and after weaning (38). They
found that weaning was associated with a significant decrease in
proportions of Bifidobacteria and Enterobacteria species as well
as in C. difficile and C. perfringens (38). Conversely, there was a
significant increase in proportions of Clostridium coccoides and
Clostridium leptum (38). In a recent study, 45 exclusively breast-
fed 5-month-old infants were randomly assigned to 1 of 3 feeding
groups to assess the effect of iron supplementation on the enteric
microbiota (98). Children were either fed pureed meats, iron and
zinc fortified cereals, or iron-only fortified cereals as the primary
complementary food until they were 9–10 months old and fecal
samples from 5 to 9 months of age were compared among the
children in the three groups (98). Actinobacterial taxa (such as
Bifidobacteria and Rothia) as well as Lactobacillales decreased over
time with Bacteroides remaining the most abundant in children
fed iron-only fortified cereals (98). Clostridium group XIVa (large
group of butyrate-producing bacteria) was much more abun-
dant in the microbiotas of the children that were fed meat (98).
Koenig et al. found that the introduction of formula and peas
to the infant’s diet was associated with an increase in the Bac-
teroidetes phylum and, after metagenomic analysis, an increase
in functional adult-microbiome genes associated with carbohy-
drate utilization and vitamin biosynthesis (9). The introduction
of solid foods to the infant diet seems to initiate the maturation of
the infant gut microbiota toward that of an adult. However, more
research is needed to clarify what specific components of a solid
food diet play the biggest role in developing the infant gut micro-
biota and how these feeding regimens affect the overall health of
the infant.
GEOGRAPHY
Intestinal microbiota differs by geographical location for a num-
ber of reasons. Microbial and environmental pressures can alter
both the repertoire of bacterial species inhabiting the region and
their abundance. Different ethnogeographic populations have dis-
tinct genetic backgrounds, regional diets, and cultural practices. Of
course, resource-replete regions also have access to better sanita-
tion and healthcare than developing nations. Thus, when studies
are designed to assess geographical differences in intestinal com-
munities, any trends are attributable to a large body of differences
other than geographical separation. Still, comparisons between
several developed and developing regions have provided some
insight into which geography-associated variables are the strongest
drivers of microbial diversity.
A comparison between continentally distinct populations led
to the emergence of distinct types of community structures, dri-
ven by composition of the Bacteroidetes phylum (28). Danish,
Spanish, Italian, French, Japanese, and American adults were dis-
tinguished by the dominant genera in the phylum being either
Prevotella or Bacteroides, or with a less pronounced Ruminococcus
signature. Interestingly, children do not develop a microbial com-
munity signature with either Bacteroides or Prevotella until after
weaning (32). A longitudinal study on Danish infants revealed
that a community structure signature was only detectable after
36 months of life, when the Bacteroidetes phylum, undetectable at
9 or 18 months, expanded in abundance (99).
A sequence-based study compared African children living the
rural lifestyle in Burkina Faso (BF) to European urban dwellers in
Florence, Italy (EU). These juxtaposed populations were selected
because BF represents a society closely resembling the ancestral
Neolithic lifestyle, accompanied by high-fiber diet of vegetables,
grains, and legumes and absence of processed foods. EU chil-
dren have a typical western diet saturated in sugars and animal
fats, accompanied by a greater caloric intake (32). Compared to
EU children, BF children are dominated by Bacteroidetes with a
reduced Firmicutes population, along with decreased Proteobac-
teria and reduced Actinobacteria. The Bacteroidetes-Firmicutes
balance has been recently hypothesized to reflect climate, in that
Firmicutes dominance is associated with colder climates necessi-
tating increased body fat percentage (100). A community structure
signature was found in this study as well, with Prevotella dominant
microbiotas being exclusive to BF and Bacteroides exclusive to EU.
Besides the differences in microbial species, BF also had raised
levels of SCFAs in their stool.
Further studies expanded the developing vs. developed coun-
try comparison to include a large cohort of pediatric and adult
samples from urban United States and rural villages in Venezuela
and Malawi. A Prevotella predominant community signature was
found in Malawian and Venezuelan microbiotas, whereas Bac-
teroides predominated in the North American samples (33). In
addition, there were far fewer differences between Venezuelan and
Malawian microbiotas, compared to the samples from USA. Taxa
discriminating the two rural communities belong predominantly
to the Firmicutes phylum with Enterococci being more common
to Venezuelan babies and different distributions of the Clostridia
class separating adults. Moreover, metagenomics revealed enrich-
ment in glycan and urease metabolic pathways in Venezuelan and
Malawian babies, indicative of enhanced ability to forage nitrogen
and glycans as an energy source from breast-milk. This enhanced
metabolic efficiency of Venezuelan and Malawian infant micro-
biotas may be an adaptation to decreased volume of nutrition
available to these infants compared to North Americans. The
Prevotella–Bacteroides split is also observed when comparing chil-
dren living in a Bangladeshi slum compared to American children
living in affluent neighborhoods (101).
Overall, geography is thought to impact the microbiota pri-
marily based on the regional lifestyle. Microbiotas throughout
the USA fail to form discrete clusters despite multicultural and
multicenter sampling (33, 102, 103). The same could be said for
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European populations, which are similar to American populations
(28, 104). Meanwhile, the microbiotas in developing nations are
divergent, but similar between geographically distinct regions with
similar dietary habits (32, 33). Importantly, the Prevotella signa-
ture is detectable in both Danish (99) and American (33) cohorts,
albeit with much more rarity. Thus, the human infant microbiome,
irrespective of genetic background, can develop along contrasting
trajectories that are dictated by regional lifestyle and diet.
ANTIBIOTICS
Broad-spectrum antibiotics are often prescribed to infants in the
Western world in an attempt to protect the developing child from
disease (105). In addition to conferring antibiotic resistance in
infancy (106), antibiotic over usage can significantly disrupt the
overall ecology of the gut microbiota, alter the abundances of res-
ident gut bacteria, and potentially bias the child toward certain
diseases (107–109).
Although the gut microbiota is rather resilient to disruptive
factors such as antibiotics (110), the ecology of this dense micro-
bial population can be severely altered if exposed to antibiotics
too early in its development and/or for long periods of time (111).
This ecological disruption combined with the decreased microbial
diversity of the infant gut can provide opportunities for enteric
pathogens (112–114). C. difficile is a common infection associ-
ated with the antibiotic disturbed gut microbiota (109). A study
including 53 infants between the ages of 0 and 13 months linked
the onset of C. difficile infections in infancy with alterations in the
infant gut microbiota (114).
Antibiotic usage in early-life can also significantly impact the
growth of otherwise dominant bacterial phyla in the human
gut (111). A study by Fouhy et al. showed that infants exposed
to ampicillin and gentamicin shortly after birth tend to harbor
higher proportions of Proteobacteria, Actinobacteria, and Lac-
tobacillus than the unexposed children for up to 4 weeks after
concluding treatment (111). These sorts of effects are even more
visible at the genus level, as seen in a study conducted by Tanaka
et al. (105). Terminal restriction fragment length polymorphism
(TRFLP) analysis of 26 infants (5 of them received oral broad-
spectrum antibiotics) showed that the subjects that received either
oral or intravenous antibiotics during the first 4 days of life have
less gut microbial diversity as well as an attenuation in coloniza-
tion with Bifidobacterium and an increase in colonization with
Enterococcus (105).
As stated above, antibiotic exposure in early life can render
the infant susceptible to numerous diseases later in life (7, 59,
83, 107, 115). Russell et al. showed that vancomycin treatment of
ovalbumin (OVA)-challenged mice in early life altered the relative
prevalence of microbial populations within the gut microbiota
and consequently increased the susceptibility of these mice to
asthma (7). A human study associated vancomycin treatment
with increased bile acid and glucose metabolism related to the
development of obesity (115). Furthermore, antibiotic therapy
given to a mouse model of adiposy in early life alters the rela-
tive abundances of bacterial populations in the intestine (107).
In addition, they showed that this antibiotic therapy in early-life
increases colonic short-chain fatty acid levels and increases in adi-
posy in these mice by altering the regulation of lipid and cholesterol
metabolism (107). There is also evidence of antibiotics playing a
role in the development of IBD in children (116–118). Shaw et al.
found that antibiotic usage during the first year of life was more
common in those diagnosed with IBD later in life (116). These
results strongly hint at a link between antibiotic usage and disease
onset, but research is needed to fully understand the mechanism by
which antibiotic-induced microbial dysbiosis influences early-life
immune development.
ROLE OF GUT MICROBIAL DYSBIOSIS IN PEDIATRIC DISEASE
This section reviews the most relevant scientific evidence associat-
ing alterations of the intestinal microbiota and pediatric diseases.
A summary of this section in included as Table 1.
NECROTIZING ENTEROCOLITIS
One of the most lethal threats to a PT infant is NEC (138, 139).
With roughly 7% of low birth weight (LBW) infants being diag-
nosed with NEC in Canada and USA (140, 141) and up to 30%
of these infants going on to die from this disease (142), there is
an enormous need to understand its etiology in order to develop
novel therapeutic interventions. NEC can have different presen-
tations depending on the age of the newborn and the gestational
time. NEC in the term infant is often due to structural abnor-
malities in the intestine and ischemic injury, and often presents
within the first week of life (143–145). NEC in the pre-term
infant that occurs in the first day of life is often due to intesti-
nal perforation, and is associated with only minor tissue necrosis
and lacks the elevated serum cytokine signature seen in classical
NEC (146). Classical NEC, which manifests in pre-term infants
1-week after birth or later, is associated with extensive intestinal
tissue necrosis (146), elevated serum proinflammatory cytokines
(147–149), and bacteremia and endotoxemia (148, 150). The eti-
ology of classical NEC likely involves the intestinal microbiota.
The premature neonate gut barrier is leakier than that of term
babies (151, 152), a trend that also holds true in animal mod-
els of classical NEC (153–155). Increased intestinal permeability
promotes bacterial translocation and may account for the endo-
toxemia and bacteremia associated with NEC. Other risk factors
for NEC include antibiotic use (156, 157) and formula feedings
(158, 159), both of which are associated with divergent microbial
communities. Breastfeeding favors growth of bacteria beneficial to
the host while formula feeding might introduce microbes not nor-
mally present in the microbiota. The Chronobacter genus is one
example of an emerging opportunistic pathogen that can cont-
aminate infant formula and is isolated from NEC patients with
higher frequency (160). Thus, the presence of unfavorable bacte-
ria in the leaky pre-term gut is being assessed as another risk factor
for NEC.
In general, surveys of the PT infant gut show a microbiota
dominated by the Firmicutes and Proteobacteria phyla (119–123,
161). Using culture-based methods, pathogenic bacteria were iso-
lated with more frequency from infants diagnosed with NEC
(162) vs. controls, with Coagulase-Negative Staphylococci as a
common pathogen. Further, culture-independent case–control
comparisons sampled the microbiota within a week of diagno-
sis and found an outgrowth of Proteobacteria in NEC compared
to controls (119, 120).
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Table 1 | Intestinal microbial dysbiosis in pediatric diseases.
Disease Evidence of dysbiosis Microorganisms identified
Necrotizing
enterocolitis (NEC)
• Antibiotics and formula feeding are risk factors for disease
development




• Disease does not occur in germ-free animals
• Disease occurs in the presence of certain bacterial
species in genetically susceptible animal models
• Intestinal microbiota is disturbed in children with disease
• Bacterial diversity was reduced between CD but not for
UC (125, 126)
• Levels of F. prausnitzii were increased in CD compared to
controls (125, 127)
• Increase in Proteobacteria for UC and CD and an absence
of Verrucomicrobia in UC patients
• Taxa negatively associated with CD: Bacteroides,
Bifidobacterium, Blautia, and F. prausnitzii (127)
• Taxa positively associated CD: Haemophilus sp.,
Neiseriaceae, Fusobacterium, Haemophilus influenzae,
and E. coli (127)
• Veillonellaceae and Pasteurellaceae specifically associated
with deep ulceration in UC (127)
Obesity • Transfer of obese mice microbiota into germ-free resulted
in weight gain
• Antibiotics, including tetracycline, glycopeptide,
macrolides, and penicillin, induce weight gain in animals
• Weight gain in children 1-3 years when antibiotics
administered before 6 months of age
• Azithromycin caused weight gain in children and
adolescent patients
• Reduced Bacteroidetes species in obese individuals
(103, 128–130)
• Increased Methanobrevibacter smithii (131)
• Increased Lactobacillus species (129, 132)
• Increased Faecalibacterium prausnitzii in obese children
(133)
Atopy and asthma • Mice deficient in the Toll-like receptor (TLR) 4 gene
develop a worsened disease
• Differences in intestinal microbiota of atopic children
compared to healthy controls
• Vancomycin, but not streptomycin, worsened asthma in
mice
• A meta-analysis of 23 studies concluded that infants born
via c-section have a 20% increase in risk of developing
asthma during childhood
• Mycobacterium vaccae (134) and Helicobacter pylori (135)
significantly reduced airway disease in mice
• Vancomycin treated mice showed a decrease in
Bacteroides groups and an increase in members of the
Lactobacillaceae family (7)
• Clostridium species induced Tregs and resulted in lower
IgE titers in a mouse asthma model (136)
Autism-spectrum
disorder (ASD)
• Altered microbiota in young children with ASD compared
to healthy controls
• Vancomycin ameliorated ASD symptoms in a small group
of children
• Bacteroides fragilis treatment reduced neurological
defects in mouse model of ASD (137)
Several prospective longitudinal studies assessed whether PT
infants who would go on to develop NEC followed a distinct
trajectory with respect to microbial succession. One such study
compared PT infants who did or did not develop NEC to healthy
term infants. They found that healthy PT infants began converging
to a term-like profile around 6 weeks of age while NEC infants had
further outgrowth of Proteobacteria at the expense of Firmicutes,
in addition to a reduction of lactose fermenters from the Veillonel-
laceae family (122). The trend toward a microbiota dominated by
Proteobacteria has been observed in further studies of the micro-
biota in NEC (119–124). Stewart et al. had the unique opportunity
to analyze the microbiotas of twins discordant for NEC from 5 days
old to over a month in age (162). A sudden outgrowth of E. coli
the week before diagnosis was found only in the NEC twin, with
a subsequent outgrowth of Klebsiella pneumoniae shortly follow-
ing diagnosis, but after commencement of antibiotic therapy. A
more comprehensive study prospectively evaluated 18 NEC and
35 control PT infants from birth to hospital discharge and found a
Proteobacteria bloom 2 weeks before diagnosis, including K. pneu-
moniae, C. perfringens, and S. epidermidis (124). A gram-negative
gut dominated by Proteobacteria should therefore be considered
a significant risk factor for NEC development. Mechanistically,
the innate sensor for bacterial lipopolysaccharide (LPS) toll-like
receptor (TLR)-4, is expressed more by the pre-term than term
infant gut in both humans (163, 164) and rodent models of pre-
term NEC (165). Moreover, in such animal models, pups lacking
TLR-4 are protected from NEC (163, 165). These findings sug-
gest that while prematurity may be the seed cause for dysbiosis,
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the microbiota of all pre-term infants does not follow the same
trajectory and for those that Proteobacteria outcompetes other
commensals, NEC becomes a much bigger threat.
Introduction of beneficial commensals, or probiotics, has
shown some promise in reducing NEC incidence. Of note, feed-
ing of Bifidobacterium to rat pups improves gut barrier integrity
and diminishes NEC incidence (155). This commensal thrives in
breast-milk and is found in the term gut a few days after birth,
although it is found less in the pre-term gut (166). This, together
with other strains of probiotic bacteria, may provide a means
to modulate NEC dysbiosis and accelerate the maturation of the
prenatal intestine (167).
INFLAMMATORY BOWEL DISEASE
Inflammatory bowel diseases comprises Crohn’s disease (CD) and
ulcerative colitis (UC), two disorders of the GIT whose global
prevalence continues to climb. Europe and North America have
the highest levels of both CD and UC incidence, with over 300
per 100,000 cases for CD and 90–505 per 100,000 cases for UC
(168) and 20–30% of diagnoses are made in the pediatric pop-
ulation (169). Host genotype plays a role in IBD, and several
genome-wide association studies (GWAS) have uncovered hun-
dreds of risk alleles associated with both UC and CD. The majority
of these are genes related to immune homeostasis in the intes-
tine such as MUC19, involved in gut barrier function, CARD9
(mucosal defense), CCL8 and IL8R (innate cell recruitment),
IL23R (mucosal T cell responses), and NOD2, an associated gene
involved in bacterial sensing (170). However, it is unlikely that
IBD is solely a host-mediated disease, as these risk alleles still only
count for a small proportion associated with disease.
The gene products of many polymorphisms tied to disease are
also involved with host conversations with intestinal microbes.
Moreover, the increasing rates of disease incidence far outpace
genetic drift in the human population, which suggests that the
environment plays a major role in IBD pathogenesis. Several
aspects of the environment have been linked to pediatric IBD,
including stress, diet, antibiotic use, and prenatal exposure to
infections and smoking (171), and all of these environmental
exposures have also been associated with aberrant intestinal micro-
biotas. Animal model studies have shown that the intestinal micro-
biota plays a critical role in disease development, as IBD does not
occur under germ-free conditions (172, 173). Analyses of fecal
microbiota consistently reveals less bacterial diversity in UC and
CD patients compared to controls, with an increased density of
adherent bacteria in biopsy samples. The loss of diversity in CD
has been attributed to fewer members of the Firmicutes phy-
lum (174). Within the phylum, Faecalibacterium and Roseburia
are depleted while the Proteobacteria family Enterobacteriaceae
increases in abundance (175–177). Some of these findings have
used hypothesis-generating approaches to place these associa-
tions into causal contexts. For example, the reduction of Fae-
calibacterium prausnitzii in IBD microbiota has been observed
extensively in the literature (178). F. prausnitzii was then shown
to induce human T-regulatory cell differentiation in vitro (179)
as well as improve gut barrier integrity in a mouse model of
colitis (180). Studies such as these, among several others, have
provided insight into the dysbiosis of adult IBD and further
findings are summarized elsewhere (181, 182). A small collection
of studies focus on the pediatric population and their findings are
highlighted below.
In a small cohort recruited in Scotland, the microbiota of
colonoscopy samples were compared between 25 children with
UC or CD and 10 healthy controls. Consistent with the adult lit-
erature, diversity was reduced between CD and controls, but this
was not true for UC. Also in stark contrast to adult studies, levels
of F. prausnitzii were increased in CD compared to controls (125).
An earlier study of children with severe UC found reduced diver-
sity in patients compared to healthy controls, as well as reduced
abundance of Firmicutes and Verrucomicrobia with an increase in
Proteobacteria including E. coli (183). However, while UC children
had not received antibiotics for at least 1 month before sampling,
they were on corticosteroid therapy, which could have contributed
to these trends.
A more comprehensive, sequence-based study by Papa et al.
explored the possibility of using stool microbial signatures as a
non-invasive diagnostic tool for pediatric IBD. With a cohort of
23 CD, 43 UC patients, and 24 controls, they were able to dis-
criminate not only IBD from controls but also UC and CD, later
applying their algorithm to a dataset of adult IBD biopsy sam-
ples with some accuracy (126). Bacterial diversity was reduced
in IBD patients and this became more apparent during active
disease and less so in remission, with an increase in Proteobac-
teria (including Escherichia and Shigella). During remission, there
was an increase in Bifidobacterium abundance. Unique to UC was
the complete absence of Verrucomicrobia, which were present in
both CD and controls. Interestingly, UC and CD patients were
more distinguishable in remission and more similar during active
disease.
All of these studies, while showing small trends, suffer from
small sample size, confounding effects of treatment, and for some,
relying on stool alone instead of biopsy samples. A recent study
done by Gevers et al. addressed these pitfalls, using a cohort of
447 children diagnosed with CD alongside 221 controls. They
obtained stool together with both ileal and rectal biopsy sam-
ples for 16S analysis alongside shot-gun sequencing on a subset
of samples (127). Patients were sampled at diagnosis, thus elimi-
nating pharmaceutical treatment as a confounder. Their findings
provided several novel insights. Several taxa were negatively associ-
ated with CD, including Bacteroides, Bifidobacterium, Blautia, and
F. prausnitzii. Taxa positively associated CD included Haemophilus
sp., Neiseriaceae, Fusobacterium, Haemophilus influenzae, and E.
coli. Veillonellaceae and Pasteurellaceae were specifically associ-
ated with deep ulceration as determined by endoscopy. Most
of these trends were much stronger in the ileal samples and
would not have been detected in the stool, where all the same
microbes were present but at much lower abundance. Gene con-
tent, predicted by the PICRUSt algorithm for ileal microbiota or
shot-gun sequenced for stool samples, revealed an enrichment of
pathobiont-promoting pathways in IBD. These include enriched
benzoate metabolism in the ileum, by-products of which have
been associated with dysbiosis and Enterobacteriaceae virulence
(184, 185). Stool samples were enriched for glycerophospholipid
and LPS metabolism, products of which have been found in
increased levels in CD and UC biopsy tissues (184). Meanwhile,
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stool microbiome genes involved in complex carbohydrate metab-
olism were diminished and may result in decreased utilization of
these substrates in the gut (186).
Taken together, there is now sufficient evidence that pedi-
atric IBD is associated with aberrant microbial communities even
before treatment occurs. It is still unclear, however, whether the
dysbiosis observed at the time of diagnosis is a cause for the disease
or an early manifestation of it. Regardless, as a dysbiotic disease,
it has been treated with probiotics in several clinical trials. There
is very minimal evidence that probiotics are effective at treating
or preventing remission of CD in children. However, in UC, the
probiotic preparation known as VSL-3 has proven as an effective
therapy for the ongoing disease and remission prevention (187).
METABOLIC DISEASE: OBESITY AND MALNUTRITION
The combination of obesity and malnutrition has had a substan-
tial impact on human health globally. Obesity and diabetes rates
have almost doubled since 1980 worldwide, more than 40 million
children under 5 were overweight in 2011 (188) and 170 million
children are malnourished (189). Diet and nutrition early in life
play an important role in these metabolic disorders. However, the
prevalence and severity of obesity and malnutrition cannot be
attributed to over-eating or food insecurity alone (190). Early-life
dietary intake is a strong driver of one’s composition of intesti-
nal microbes (191). In turn, diet driven alteration of the intestinal
microbiota can feed back into host metabolism and immunity,
with differing consequences dependent on the composition and
metabolic potential of the colonizing microbes (192). Early in life,
weight gain and height are important measures of human health,
and are surrogate markers for nutritional status. In both malnu-
trition and obesity, the interrelationship between the microbiota,
metabolism, and immunity plays an important role in determining
outcomes of severity of diseases seen in malnourished and obese
humans, such as environmental enteropathy (EE) in malnourished
children and early onset of type 2 diabetes in obese children (193).
Obesity
In obesity, seminal early research implicated the composition of
the intestinal microbiota as mediators of weight gain, as the ratio
between Bacteroidetes and Firmicutes in the gut correlated with
the ability of the host to extract energy from their diet (128). Fur-
thermore, in twins discordant for obesity, transfer of their micro-
biota into germ-free mice was sufficient to account for their vari-
ations in weight, independent of genetics (194). The mechanisms
that the microbiota use to signal a shift in host metabolism include
signaling through TLR5 (195), glucagon-like peptide (GLP)-1/2
(196), and mediating systemic LPS levels (197). Thus, not only
microbiota function, but altered immune function is linked to the
pathophysiology of obesity. Obesity has an inflammatory compo-
nent that can account for the development of metabolic disease,
reflected by higher levels of circulating inflammatory proteins,
increased adipokine secretion by tissues, and dysregulated activa-
tion of leukocytes across various tissue sites, including the liver
and brain (198).
It is now clear that early-life changes in microbiota compo-
sition can alter susceptibility to developing obesity later in life.
As discussed previously, mode of delivery at birth can alter the
early-life microbial community, where the gut microbiota of chil-
dren delivered by C-section is more similar to that of the skin
microbiota, rather than vaginal microbiota. In a study of obese
Brazilian children, subjects born by C-section had a significantly
higher risk for obesity as young adults compared to those born
by vaginal delivery (199). Similarly, children fed infant formula
rather than breast-milk during the first 6 months of life were more
than twice as likely to be obese later in life (200). Aside from
nutritional intake early in life, many children are exposed to antibi-
otics throughout their childhood. Sub-therapeutic doses of several
classes of antibiotics have widely been used as early-life growth-
promoters in the agriculture industry for decades. Mechanisms
of this effect were unclear until recently, where a study by Cho
et al. showed these sub-therapeutic doses are sufficient to alter the
intestinal microbiota, which resulted in enrichment of key micro-
bial genes involved in carbohydrate metabolism to create SCFAs,
as well as systemic changes to hepatic lipid and cholesterol metab-
olism, leading to increased adiposity in young mice (107). Thus,
low levels or exposure to antibiotics can induce subtle shifts in
the microbial ecosystem, selecting for an environment more con-
ducive for weight gain and energy harvest. Epidemiological studies
show early-life antibiotic use and obesity are correlated, as states in
the U.S. with the highest obesity rates also have the highest rates of
antibiotic use (188). Many studies have shown presence/absence
of specific microbes can modulate and program life-long changes
in immunity (201), yet future studies must assess in greater detail
how these changes could impact metabolic disease progression. By
understanding the differing energy harvest and metabolic capa-
bilities of each child’s gut microbiota, we may be able to create
microbiota-based interventions to reverse susceptibility to obe-
sity early in life. A recent study showed that treatment of obese
mice with Akkermansia muciniphila reduced high-fat diet-induced
metabolic disorders, including fat-mass gain, metabolic endotox-
emia, adipose tissue inflammation, and insulin resistance (202).
Colonization with Akkermansia mucinophila increased intesti-
nal endocannabinoid levels, controlling inflammation, and also
increased the thickness of the inner mucus layer. This treatment
required viable A. mucinophila, highlighting the importance of
active metabolic output of the bacterium. This study and future
efforts hold hope that susceptibility to obesity could be controlled
early in life through the microbiota and disease outcomes of
obesity could also be improved by probiotics.
Malnutrition
Function and composition of the intestinal microbiota also plays a
key role in the development and severity of malnutrition. By trans-
ferring the feces from Malawian twins discordant for severe protein
malnutrition into germ-free mice, Smith et al. were able to show a
direct role for the microbiota in mediating symptoms of malnutri-
tion (203). Furthermore, germ-free mice fed a Malawian diet and
Malawian microbes lost weight quickly, and this effect could not be
fully reversed after feeding with a diet of therapeutic food, imply-
ing changes in the microbiota can persistently alter host immunity
and metabolism. Since microbiota can mediate the impact of mal-
nutrition, early-life fecal–oral microbial exposure during a critical
window of growth and development in children can have a last-
ing impact on the host’s ability to derive nutrients from the diet,
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resulting in EE (204). While fecal-oral pathogen exposure can
significantly alter the early-life gut microbiota and lead to diar-
rhea and stunting (205), EE presents as a sub-clinical disorder
characterized by villous blunting, crypt hyperplasia, increased per-
meability, chronic inflammation, and malabsorption in the small
intestine (204, 206). It is hypothesized that in regions with poor
sanitation, children become exposed to increased levels of fecal-
associated bacteria that can colonize the small intestine and lead
to EE. Nutritional interventions are not sufficient to reverse symp-
toms of malnutrition in two-thirds of children, suggesting that the
microbiota composition in the small intestine may skew the inter-
actions between immunity and metabolism to a scenario where
nutrient uptake and microbe-host mutualism are not favored
(193). In this way, EE is thought to have a major impact on out-
comes of malnutrition early in life, which can lead to persistent
loss of gut function, immune function and cognitive ability (207).
Mechanisms explaining how the microbiota may impact EE and
malnutrition are yet to be elucidated, although there are many
studies implicating a link between early-life diet and environ-
mental exposures altering immunity and the microbiota, which
can drive the pathophysiology and diseases related to malnutri-
tion in a paradoxically similar way to how the microbiota could
impact obesity early in life. As the efficacy of nutritional recov-
ery after early-life malnutrition remains low, a seminal study by
Trehan et al. noted a significant improvement in nutritional recov-
ery and mortality rates post-antibiotic treatment in children with
severe-acute malnutrition (208). The authors did not sequence the
microbiota in these children to correlate differences in recovery
rate from severe-malnourished, although one can speculate that
the antibiotic treatment (amoxicillin) shifted the microbiota into
a compositional arrangement more favorable for nutrient uptake.
A critical early window exists in a child’s life where its envi-
ronmental exposures (including diet and microbes) can shift
the immune–metabolism–microbiota interactions to pathophys-
iological states, which lead to alterations in host growth rates,
metabolism, and immunity, ultimately resulting in diseases relat-
ing to obesity and malnutrition (such as type 2 diabetes and EE,
respectively). A recent study suggests the impact of diet and envi-
ronmental change stresses on the host can be passed on maternally
to children, through epigenetic modulation of the DNA by methy-
lation (209). Thus, maternal dietary and microbial exposures are
also crucial to the development of the microbiota early in life, as
children may inherit genes with differing potential for predisposi-
tion for malnutrition or obesity, based on the diet of their mother.
Future studies must focus not only on early-life therapeutic inter-
ventions to promote improved intestinal health to combat obesity
and malnutrition, but also focus on maternal health to achieve a
holistic approach to quelling the impact malnutrition and obesity
have on society today.
ASTHMA AND ATOPY
The atopic diseases (atopic dermatitis, allergic rhinitis, allergic
conjunctivitis, anaphylaxis, and asthma) are characterized by IgE-
mediated hypersensitivity to an external antigen (210). Strachan’s
hygiene hypothesis, proposed in 1989, suggested that exposure of
children to infectious agents during infancy will decrease their
susceptibility to hyper-inflammatory diseases later in life (211). A
recent example of testing this theory was conducted by Ege et al.
in Central Europe; they found that children growing up on farms
experienced a wide range of microbial exposures and tended to be
protected from childhood asthma and other atopic diseases (212).
Significant changes in gut microbiota along with notewor-
thy changes in immune development and diseases paralleled the
industrial revolution, suggesting that environmentally induced
changes in the gut microbiota are associated with the devel-
opment of hypersensitivity diseases. The prevalence of asthma
and allergies has continued to rise in industrialized countries
and in developing countries where living conditions and hygiene
standards are becoming more like those of the Western world
(213). Consequently, higher sanitation standards and more read-
ily available antibiotics are likely decreasing our exposure to early
childhood microbial antigens at the expense of our immune
development (7, 213).
The microflora hypothesis is an extension of Strachan’s hygiene
hypothesis in that it argues that there are critical interactions that
must occur between our gut microbiota and our immune system
in early life in order to circumvent the development of hypersen-
sitivities (214). Studies in germ-free mice show the polarization
of the post-birth immune system toward a T-helper 2 cell (TH2)
driven immune response (215). With the restoration of the gut
microbiota, there is a shift toward a TH1 and TH17 dominated
immune phenotype, suggesting that the gut microbiota is impor-
tant in establishing the balance between the TH1/TH2 subtypes
in early life (a balance often disrupted in subjects with atopy)
(215–217).
A number of mouse model studies aim to identify that bacterial
taxa play a significant role in preventing or promoting the develop-
ment of atopy. Perinatal antibiotic treatment of OVA-challenged
mice (asthma-induced) has been shown to exacerbate the dis-
ease potentially by increasing serum and surface bound IgE as
well as decreasing T-regulatory cell accumulation in the colon
(218). Arnold et al. show that infection of asthma-induced neonate
mice versus adult mice with Helicobacter pylori protects these mice
from airway hyperresponsiveness, tissue inflammation, and goblet
cell metaplasia (common asthma characteristics) (135). Further-
more, Cahenzli et al. provide evidence in mice that a less diverse
gut microbiota in early life is associated with elevated mast cell
surface bound IgE and exaggerated systemic anaphylaxis (219).
Though these studies provide insight for the relationship between
gut microbiota and the immune system, researchers are question-
ing whether specific microbes are actually required to prevent
atopy development or whether the metagenomic and metabolomic
profiles of the gut microbiota as a whole should be the main focus.
For example, the gut microbiota promotes immune tolerance
through the regular stimulation of pattern-recognition receptors
(PRRs) and through the production of metabolites (e.g., SCFA)
(94, 220). Establishing this immune tolerance to external anti-
gens and host microbes is necessary to prevent the development
of hypersensitivity reactions, as T-regulatory cells (+FoxP3) are
critical in maintaining the TH1/TH2 balance (94). SCFAs have
been shown to play a role in regulating the proliferation of colonic
T-regulatory cells (94). These microbial-derived metabolites may
be the key to the microbial-host crosstalk that influences systemic
inflammation. Low levels of i-butyric, i-valeric, and valeric acids in
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stool samples from children 1 year of age were associated with the
development of food allergy at 4 years of age; however, analysis of
the gut microbiota composition was not conducted (221). A recent
study showed that the gut microbiota metabolized a high-fiber diet
fed to adult mice and this in turn increased the amount of circu-
lating SCFA and consequently decreased allergic inflammation in
the lungs of these mice (95). Additional research that focuses on
the early-life microbiota is necessary to determine whether these
metabolites may be influencing the development of our immune
system and thus potentially biasing us toward or away from certain
inflammatory diseases.
The majority of human studies regarding the early-life gut
microbiota and the development of atopic disease focuses on the
role of variables such as mode of delivery (vaginal vs. cesarean
birth), feeding methods (breast-milk vs. formula/solid food diet),
and early-life antibiotic exposure. Though the infant gut micro-
biota is influenced significantly by the child’s mode of birth (56),
there are conflicting results regarding the association of birth mode
with the development of atopic diseases. For example, according
to Kolokotroni et al. children born by cesarean section are at an
increased risk of developing asthma later in life, yet van Nimwe-
gen et al. argue that mode of birth is less significant than the place
of birth (hospital or home) in the development of the intestinal
microbiota and asthma (222, 223).
Breastfeeding is a significant contributor to the development of
the infant gut microbiota (224). As discussed earlier in this review,
breast-fed babies typically have higher numbers of Bifidobacteria
and lower numbers of Bacteroides and Atopobium when compared
to infants that are exclusively formula-fed (83, 84), whether or
not data such as this can be associated with the protection or
promotion of atopic disease is still under debate (225–227). How-
ever, higher proportions of certain non-digestible HMOs have
been associated with a decreased risk of respiratory disease in
infants (228).
Antibiotic treatment during the first few years of life has an
equally significant impact on the bacterial ecology of the infant
gut (107, 109, 111). Epidemiological studies in humans indi-
cate that broad-spectrum antibiotic exposure may play a role in
the development of asthma and atopy. Muc et al. conducted a
questionnaire-based study and found that antibiotic exposure in
the first year of life plays a significant role in the development
of asthma and allergic rhinitis in children (229). Additionally,
Hoskin-Parr et al. assessed data from 4952 children enrolled in
the Avon Longitudinal Study of Parents and Children and found
a dose-dependent association between antibiotic usage during the
first 2-years of life and the development of asthma at 7.5 years of
age (230).
The development of atopic disease in children is characterized
by an extremely complex network of environmental and genetic
factors, but as the current research shows, the role of the gut
microbiota cannot be ignored.
AUTISM-SPECTRUM DISORDER: THE GUT-BRAIN AXIS
The gut–brain axis is the biochemical signaling that takes place
between the GIT and the nervous system. This interaction involves
the composition and function of the intestinal microbiota, as it has
been shown to alter hormones relating to neurochemical changes
in the brain that can modulate the behavior of the host, including
anxiety, cognition, stress, mood, and energy-level (231). There are
many recent reviews covering this phenomenon extensively (232,
233), so for the purposes of this review, we focus on how early-life
changes in the microbiota can alter susceptibility to neurolog-
ical disease, specifically autism-spectrum disorder (ASD). ASD
is a collection of neurodevelopmental changes in children where
they exhibit complex behavioral changes in their abilities in social
interaction and communication, as well as presence of behaviors
similar to obsessive–compulsive disorder, including repetitive and
narrow interests. While the disease impacts the brain, gastroin-
testinal symptoms are commonly described in children with ASD
(234, 235), and studies have identified the presence of inflam-
matory infiltrate and histopathology in biopsies of children with
ASD, including increased numbers of cytotoxic T cells, CD19+ B-
cells, and increased enteric IgG1/4 (236, 237). Possibly related to
these GIT immune changes and dysfunction, some studies have
demonstrated an altered composition of intestinal microbiota in
young children with ASD compared to healthy control children
with typical neurological function (238–242). These data should
be interpreted with caution, however, since these studies are all
relatively small and ASD children tend to have alternate diets and
antibiotic exposures in relation to healthy, typical children. The
microbiota composition may be of clinical importance, as a clin-
ical study treated children with ASD with vancomycin and found
a high efficacy of recovery from symptoms (243). However, this
was a small study and the validity of antibiotic treatment in ASD
needs to be assessed with more data.
When identifying a role for the microbiota in ASD, rather
than making predictions based on taxonomic sequence data,
recent studies have been studying the metabolite secretions of
gut microbes and the impact of these microbiotas on host serum
metabolites. A potential mechanism behind ASD symptoms could
be neuro-active metabolites mediated by or produced by the
microbiota, which could disseminate systemically and penetrate
the blood–brain barrier. A recent study by Hsiao et al. sought
to understand which bacterially produced metabolites modulate
progression of ASD by taking advantage of the maternal immune
activation (MIA) mouse model, in which mice are known to dis-
play features of ASD. They demonstrated that MIA mice exhibit
increased intestinal permeability and alterations in the micro-
biota and serum metabolite profile compared to control mice
(137). Remarkably, the authors found that oral treatment with
B. fragilis reversed gut permeability and reduced the neurologi-
cal defects in the MIA mice similar to ASD, including anxiety-like
and communicative behavior, while also modulating the serum
metabolome. Furthermore, treatment of a single metabolite that
is upregulated in MIA mice, restored to normal levels by B. fragilis,
induced behavioral abnormalities, highlighting the importance of
the serum metabolome profile in ASD (137). This research opens
up exciting avenues for future studies in ASD and the microbiome
in the early stages of life, and hints at the ability of beneficial
microbes to modulate symptoms of ASD. Many studies have
suggested early-life exposure to Bifidobacterium or Lactobacillus
species modulate behavior in mice (244, 245), and whether these
more classical probiotic strains could impact the development of
ASD in children remains to be seen. Other studies have altered the
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hypothesis to argue that it is microbial metabolites meditating the
symptoms of ASD. In support of this, elevated SCFA concentra-
tions in the stool of children with ASD have been reported (246).
The microbiota early in life produces lower levels of SCFAs com-
pared to adults, since they lack the prevalence of the microbes
with the enzymes for their production and generally eat a diet low
in complex dietary carbohydrates necessary for the production of
SCFAs. Direct exposure of the SCFA propionate to animal brain
tissue results in the development of autistic-like behavior (247,
248). Thus, an increase in these metabolites may lead to alterations
in brain function.
Once considered in the realms of “pseudo-science,” there has
been a groundswell of attention in the role of intestinal microbes
and metabolic changes in neurodevelopmental disorders in chil-
dren, such as ASD. The complexity and heterogeneity of ASD
makes it a challenging disease to understand and reverse thera-
peutically. By taking the new research on the microbiota’s role
in the gut-brain access, and the knowledge of importance in the
early-life changes, the next-generation of therapies could focus on
therapies that increase bacterial homeostasis and barrier function.
CONCLUSION
Microbiota surveys worldwide have yielded important lessons
regarding what influences the microbial composition of the adult
intestine, and how this is associated with different diseases. The
shift in the Firmicutes/Bacteroidetes ratio is a constant finding
among several of the studies looking at disease. Also, the abun-
dance of Prevotella is higher in indigenous regions of the world
where there is a much lower incidence of immune-mediated dis-
eases. However, these findings arise from studies done in adults,
and the intestinal microbiota during the first 3 years of life differs
significantly from adulthood. The microbial community “signa-
tures” associated with the diseases reviewed here do not appear
until after 2–3 years, yet it is known that alterations to the early-
life microbiota are closely associated the development of these
diseases. A recent study in children newly diagnosed with IBD
showed that the microbial alterations accompanying disease were
different than the changes observed in studies done after diagno-
sis and during pharmacological treatment (127). This important
study suggests that the microbial alterations observed after the
disease manifests clinically may not be involved directly in disease
pathogenesis and may in fact be, at least in part, a product of the
disease manifestations. It is critical to perform additional micro-
biota studies during the first year of life, a period during which the
microbiota composition may give a more accurate portrayal of the
microbial conditions that are involved in pathogenesis.
To date, the vast majority of the microbiota studies have focused
on the taxonomic profiles of the microbial communities. How-
ever, metagenomic studies have shown that different microbes in
the gut do not necessarily reflect a different metabolic profile,
emphasizing the high degree of redundancy in the biochemical
activity among different bacterial taxa (249). Thus, exploring the
metagenomic and metabolomic profiles that result from early-life
microbial changes associated with disease may provide a better
understanding of the role of the microbiota (and their molecules)
in the disease process, and may also produce biomarkers of disease
before it manifests clinically.
Given that children undergo a drastic succession of microbial
changes over a few months, it is clearly important to understand
how and when these changes occur. There is a real need for large
cohort studies that survey the infant microbiome and metabolome
from birth and during at least the first year of life, a period of time
most often free of the diseases discussed here yet full of micro-
bial and metabolic changes that may explain the process of later
disease emergence. A full understanding of this disease-related
changes could allow us to create interventions that rationally shift
the microbiota in infants to construct a healthy intestinal envi-
ronment from a young age. A “critical window” exists early in life
where interventions could have more of a profound, long lasting
impact on health. Thus, understanding the microbiota changes
during this critical window of time will be of great importance for
disease prevention.
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